Objective:
To evaluate the efficacy and safety of once-weekly survodutide in reducing body weight in patients with obesity without diabetes.
Approach:
- Mean body weight decreased by about 12% in the 3.6 mg group and 13% in the 6 mg group compared to over 5% in the placebo group.
- 73% of patients in the 3.6 mg group and 72% in the 6 mg group achieved at least 5% weight loss, compared to 46% in the placebo group.
- Higher proportions of patients in the survodutide groups achieved greater weight loss thresholds: 10% (55% and 57% vs. 26%), 15% (36% and 46% vs. 12%), and 20% (25% and 29% vs. 7%).
- Greater reductions in waist circumference and improvements in metabolic measures were observed in the survodutide groups.
- Liver fat content decreased by 63% in the 6 mg group compared to 25% in the placebo group.
- The safety profile was characterized primarily by adverse gastrointestinal events, with nausea, vomiting, diarrhea, and constipation occurring more frequently among the patients receiving survodutide.
- No active comparator was included, limiting direct comparisons with existing obesity medications.
- A significant number of patients discontinued treatment before week 76, which may affect the results.
- Patients with diabetes, uncontrolled hypertension, recent cardiovascular events, and inadequately controlled mood disorders were excluded.
- Weight loss in the placebo group was greater than anticipated.
Key Findings:
Interpretation:
Once-weekly survodutide led to significantly greater reductions in body weight compared to placebo in adults with obesity, highlighting its potential as a treatment option.
Limitations:
Conclusion:
The trial demonstrated the potential of survodutide for weight management in patients with obesity.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
